MCID: CNN004
MIFTS: 35

Connective Tissue Cancer

Categories: Cancer diseases

Aliases & Classifications for Connective Tissue Cancer

MalaCards integrated aliases for Connective Tissue Cancer:

Name: Connective Tissue Cancer 12 14
Neoplasms, Connective Tissue 41 69
Neoplasm of Connective Tissues 12
Tumour of Connective Tissue 12
Connective Tissue Neoplasm 12

Classifications:



External Ids:

Disease Ontology 12 DOID:201
MeSH 41 D009372
SNOMED-CT 64 126598008 254821003
UMLS 69 C0027656

Summaries for Connective Tissue Cancer

Disease Ontology : 12 A musculoskeletal system cancer that is located in connective tissue.

MalaCards based summary : Connective Tissue Cancer, also known as neoplasms, connective tissue, is related to sarcoma and connective tissue benign neoplasm. An important gene associated with Connective Tissue Cancer is EWSR1 (EWS RNA Binding Protein 1), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Relaxin signaling pathway. The drugs Dienogest and Nandrolone have been mentioned in the context of this disorder. Affiliated tissues include connective tissue, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Related Diseases for Connective Tissue Cancer

Diseases in the Connective Tissue Cancer family:

Connective Tissue Benign Neoplasm

Diseases related to Connective Tissue Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 95)
# Related Disease Score Top Affiliating Genes
1 sarcoma 29.4 CREB3L2 EWSR1 FUS MDM2 PDGFB SS18
2 connective tissue benign neoplasm 11.2
3 kaposi sarcoma 10.8
4 chondrosarcoma 10.8
5 fibrosarcoma 10.8
6 spindle cell sarcoma 10.8
7 pleural cancer 10.8
8 epithelioid cell synovial sarcoma 10.7 SSX1 SSX2B
9 ring chromosome 4 10.7 COL1A1 PDGFB
10 bladder sarcoma 10.7 CD99 EWSR1
11 tibial adamantinoma 10.7 CD34 SSX1
12 extraskeletal mesenchymal chondrosarcoma 10.7 SSX1 SSX2B
13 actinic cheilitis 10.7 MDM2 TP53
14 cellular neurofibroma 10.7 CD34 TP53
15 testicular fibroma 10.7 CD34 CD99
16 soft tissue sarcoma 10.6 EWSR1 MDM2 TP53
17 bone epithelioid hemangioma 10.6 CD34 EWSR1
18 ring chromosome 7 10.6 CDK4 MDM2 TP53
19 undifferentiated embryonal sarcoma of the liver 10.6 CDK4 MDM2
20 bednar tumor 10.6 COL1A1 PDGFB
21 conventional central osteosarcoma 10.6 EWSR1 MDM2
22 infiltrating angiolipoma 10.6 CDK4 MDM2
23 periosteal osteogenic sarcoma 10.6 CDK4 MDM2 TP53
24 dedifferentiated liposarcoma 10.6 CDK4 MDM2 TP53
25 retina lymphoma 10.6 CD34 CD68
26 small cell sarcoma 10.6 CDK4 MDM2 TP53
27 spindle cell lipoma 10.6 CDK4 MDM2
28 embryonal sarcoma 10.6 CDK4 MDM2 TP53
29 lipomatosis, multiple 10.6 CDK4 FUS MDM2
30 extraosseous osteosarcoma 10.6 CD34 CDK4 MDM2
31 biphasic synovial sarcoma 10.6 EWSR1 SSX1
32 extraskeletal ewing sarcoma 10.6 CD99 EWSR1 FUS
33 extracutaneous mastocytoma 10.6 CD34 CD68
34 sternum cancer 10.6 CD34 CD68
35 cellular schwannoma 10.6 CD34 MDM2 TP53
36 retinal cancer 10.6 CDK4 MDM2 TP53
37 inflammatory mfh 10.6 CD68 CDK4 MDM2
38 grade iii astrocytoma 10.6 CDK4 MDM2 TP53
39 sensory system cancer 10.6 CDK4 MDM2 TP53
40 myxosarcoma 10.6 CD68 MDM2 TP53
41 ocular cancer 10.6 CDK4 MDM2 TP53
42 bone ewing's sarcoma 10.6 CD99 EWSR1 PDGFB
43 mesenchymal cell neoplasm 10.6 CD34 CREB3L2 EWSR1
44 liver angiosarcoma 10.6 CD34 CDK4 TP53
45 meninges sarcoma 10.6 CD34 CREB3L2 TP53
46 leiomyosarcoma 10.6 CDK4 MDM2 TP53
47 fibrosarcoma of bone 10.6 CDK4 CREB3L2 MDM2
48 melanotic neurilemmoma 10.6 CD34 CD68
49 sarcomatoid squamous cell skin carcinoma 10.6 CD34 CD68 TP53
50 kidney hemangiopericytoma 10.6 CD34 SS18 SSX2B

Graphical network of the top 20 diseases related to Connective Tissue Cancer:



Diseases related to Connective Tissue Cancer

Symptoms & Phenotypes for Connective Tissue Cancer

GenomeRNAi Phenotypes related to Connective Tissue Cancer according to GeneCards Suite gene sharing:

25 (show all 14)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-111 9.64 TLE1
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-112 9.64 FUS
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 9.64 CDK4
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 9.64 SSX2B
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-191 9.64 SSX2B
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-203 9.64 EWSR1
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-206 9.64 SSX1
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 9.64 EWSR1
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-40 9.64 FUS
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 9.64 CDK4 EWSR1
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 9.64 FUS TLE1
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 9.64 CDK4 EWSR1 FUS SSX1 SSX2B TLE1
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-84 9.64 EWSR1
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-89 9.64 EWSR1

MGI Mouse Phenotypes related to Connective Tissue Cancer:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 pigmentation MP:0001186 9.35 CDK4 COL1A1 MDM2 PDGFB TP53
2 renal/urinary system MP:0005367 9.17 CAMKMT CDK4 COL1A1 MDM2 PDGFB TP53

Drugs & Therapeutics for Connective Tissue Cancer

Drugs for Connective Tissue Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 553)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dienogest Approved Phase 4 65928-58-7
2
Nandrolone Approved, Experimental, Illicit, Investigational Phase 4 62-90-8, 434-22-0 9904 229455
3
Nandrolone decanoate Approved, Illicit Phase 4 360-70-3 9677
4
Desogestrel Approved Phase 4 54024-22-5 40973
5
Goserelin Approved Phase 4,Phase 3 65807-02-5 5311128 47725
6
Calcium Carbonate Approved, Investigational Phase 4,Phase 3 471-34-1
7
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 341031-54-7, 557795-19-4 5329102
8
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
9
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
10
Tamoxifen Approved Phase 4,Phase 2,Phase 1 10540-29-1 2733526
11
Anastrozole Approved, Investigational Phase 4,Phase 3 120511-73-1 2187
12
Menthol Approved Phase 4,Phase 3,Early Phase 1 2216-51-5 16666
13
Hydroxocobalamin Approved Phase 4 13422-51-0 5460373 44475014 11953898
14
Zinc Approved, Investigational Phase 4 7440-66-6 32051 23994
15
Zinc oxide Approved Phase 4 1314-13-2
16
Lidocaine Approved, Vet_approved Phase 4,Not Applicable 137-58-6 3676
17
Cetrorelix Approved, Investigational Phase 4 120287-85-6 25074887 16129715
18
Acetaminophen Approved Phase 4,Phase 2 103-90-2 1983
19
Ibuprofen Approved Phase 4,Phase 2,Not Applicable 15687-27-1 3672
20
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
21
Morphine Approved, Investigational Phase 4,Phase 1,Phase 2 57-27-2 5288826
22
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
23
Ethanol Approved Phase 4,Phase 3 64-17-5 702
24
Mifepristone Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 84371-65-3 55245
25
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 57-83-0 5994
26
Leuprolide Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 53714-56-0 657181 3911
27
Denosumab Approved Phase 4,Phase 3,Phase 2 615258-40-7
28
Levonorgestrel Approved, Investigational Phase 4,Phase 1 797-63-7, 17489-40-6 13109
29
Misoprostol Approved Phase 4,Phase 2 59122-46-2 5282381
30
Dalteparin Approved Phase 4,Phase 1,Not Applicable 9005-49-6
31
Heparin Approved, Investigational Phase 4,Phase 1,Not Applicable 9005-49-6 46507594 772
32
Celecoxib Approved, Investigational Phase 4,Phase 2,Phase 1 169590-42-5 2662
33
Tranexamic Acid Approved Phase 4,Early Phase 1 1197-18-8 5526
34
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7 9579578 4594
35
Letrozole Approved, Investigational Phase 4,Phase 1 112809-51-5 3902
36
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
37
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
38
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
39
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
40
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
41
B-Carotene Approved, Nutraceutical Phase 4 7235-40-7 5280489
42
Cholecalciferol Approved, Nutraceutical Phase 4 67-97-0 10883523 5280795 6221
43
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
44
Methylcobalamin Approved, Experimental, Investigational, Nutraceutical Phase 4 13422-55-4
45
Niacin Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 59-67-6 938
46
Nicotinamide Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 98-92-0 936
47
Pyridoxal Approved, Nutraceutical Phase 4 66-72-8 1050
48
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
49
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved Phase 4 83-88-5 493570
50
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 59-43-8 1130

Interventional clinical trials:

(show top 50) (show all 1146)

# Name Status NCT ID Phase Drugs
1 Endometrial Preparation Before Operative Hysteroscopy in Premenopausal Women Unknown status NCT02440750 Phase 4 Dienogest;Ulipristal acetate
2 Study of the Efficacy of Dienogest in the Treatment of Uterine Leiomyomas When Compared to Desogestrel and Goserelin Unknown status NCT01738724 Phase 4 Dienogest;Goserelin;Desogestrel
3 High Intensity Focused Ultrasound Ablation Virus Myomectomy to Treat Uterine Fibroids Unknown status NCT01239641 Phase 4
4 Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors Unknown status NCT00777504 Phase 4 usage oral angiogenesis inhibitor;stop oral angiogenesis inhibitor
5 Imatinib in KIT-negative Systemic Mastocytosis Completed NCT01297777 Phase 4 Imatinib Mesylate
6 Fibroids in Women of Reproductive Age and Women Pregnancy Completed NCT02620345 Phase 4 Dydrogesterone M ( case 1 );Dydrogesterone M ( case 2 )
7 Intra-arterial Lidocaine for Pain Control Post Uterine Fibroid Embolization Completed NCT02293447 Phase 4 Lidocaine per-embolization;Lidocaine post-embolization
8 Safety Study of ExAblate for the Treatment of Uterine Fibroids Completed NCT01142791 Phase 4
9 The FIRSTT: Comparing MRgFUS(MR-guided Focused Ultrasound) Versus UAE (Uterine Artery Embolization)for Uterine Fibroids. Completed NCT00995878 Phase 4
10 Novel MRI Strategies as a Non-invasive Biomarker in Women With Uterine Fibroids Completed NCT00746031 Phase 4 GnRH analogue (Zoladex);GnRH antagonist-Cetrorelix
11 Randomized Controlled Trial (RCT)Comparing GYNAECARE MORCELLEX Versus ROTOCUT GI Tissue Morcellators Completed NCT00743080 Phase 4
12 Safety Trial of Magnetic Resonance (MR) Guided Focused Ultrasound Surgery (FUS) in Women With Uterine Fibroids Wishing to Pursue Pregnancy in the Future Completed NCT00180739 Phase 4
13 MR Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids Completed NCT00166270 Phase 4
14 Efficacy Study of Magnetic Resonance (MR) Guided Focused Ultrasound in the Treatment of Large Fibroids Completed NCT00159328 Phase 4
15 Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor Completed NCT00793871 Phase 4 Sunitinib Malate (SU011248)
16 Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib Mesylate Completed NCT00510354 Phase 4 Imatinib mesylate
17 Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST) Completed NCT00171977 Phase 4 Imatinib Mesylate
18 Effectiveness of IV Acetaminophen and IV Ibuprofen in Reducing Post Procedural Pain in the UFE Procedure Completed NCT02227316 Phase 4 IV Ibuprofen;IV Acetaminophen;IV Placebo
19 Effects of Tamoxifen in Premenopausal Women With Benign Breast Disease Not at High-Risk of Developing Breast Cancer Completed NCT00999921 Phase 4 Tamoxifen;Evening Primrose Oil
20 Retreatment of Recurrent Dupuytren's Contractures Completed NCT01498640 Phase 4
21 MRI Results in Dupuytren's Contracture Before and After Injection With Xiaflex Completed NCT01450397 Phase 4
22 Intravenous or Intra-abdominal Local Anesthetics for Postoperative Pain Management. Completed NCT01492179 Phase 4 Normal saline;Intravenous Lidocaine;Intra-abdominal Lidocaine
23 Efficacy and Safety of Xiaflex Injection for Treatment of Dupuytren's Contracture of the Thumb Completed NCT01265420 Phase 4
24 Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients Completed NCT01402089 Phase 4 Sunitinib;Erlotinib;Midazolam;Caffeine
25 Efficacity Assessment of PREVADH® in Adhesion Prevention in Gynaecologic Surgery Completed NCT01388907 Phase 4
26 A Prospective Study Comparing Contour SE™ Microspheres to Embosphere® Microspheres for Treating Symptomatic Uterine Fibroids With Uterine Fibroid Embolization (UFE) Completed NCT00628901 Phase 4
27 Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat Osteosarcoma Recruiting NCT01669369 Phase 4 Lithium Carbonate;Placebo
28 A Study on the Mifepristone Tablets in the Treatment of Symptomatic Uterine Fibroids With Safety and Efficacy Recruiting NCT03210324 Phase 4 Mifepristone tablets
29 Ulipristal Use in Chinese Population Recruiting NCT02825719 Phase 4 Ulipristal acetate;Ferrous sulphate;Tranexamic Acid
30 Ulipristal Acetate for the Preoperative Management of Hypoechoic Cellular Leiomyomas Recruiting NCT02361905 Phase 4 ulipristal acetate;Leuprolide acetate
31 Ulipristal Acetate Versus GnRH Analogue Treatment Before Hysteroscopic Resection of Uterine Leiomyoma Recruiting NCT02361879 Phase 4 ulipristal acetate;Leuprolide acetate
32 Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004 Recruiting NCT03301857 Phase 4 Cohort A Denosumab
33 Prospective Trial Comparing the Performance Profiles of Two Non-Cross-Linked Porcine Dermal Matrices in Abdominal Wall Reconstruction Recruiting NCT02228889 Phase 4
34 Aromatase Plus GnRH Analogue Versus Ulippristal Acetate in Uterine Fibroids Recruiting NCT03421639 Phase 4 Ulipristal acetate;Aromatase inhibitor plus GnRH analog
35 Treatment of Heavy Menstrual Bleeding in Women With Uterine Fibroids Recruiting NCT03317795 Phase 4 Levonorgestrel IUS;Tranexamic Acid
36 Trial Comparing Treatment Strategies in Dupuytren's Contracture Recruiting NCT03192020 Phase 4 Collagenase Clostridium Histolyticum 2.9 MG/ML [Xiaflex]
37 Collagenase Injection vs Percutaneous Needle Aponeurotomy for Dupuytren's Disease Recruiting NCT03000114 Phase 4 XIAFLEX
38 The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib Recruiting NCT02800330 Phase 4 Esomeprazole 40mg concomitantly;Esomeprazole 40mg before;Regorafenib 160mg or 120mg
39 Prospective Randomized Trial Between Needle Fasciotomy and Xiapex for Dupuytrens Contracture Recruiting NCT02476461 Phase 4 xiapex
40 Misoprostol for Reduction of Blood Loss During Fibroid Surgery Recruiting NCT02209545 Phase 4 Misoprostol;Placebo
41 Pilot of Letrozole for Uterine Myomas Active, not recruiting NCT02470741 Phase 4 Letrozole
42 Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib Active, not recruiting NCT00756509 Phase 4 Nilotinib
43 Dupuytren´s Disease Study. Primary Disease, MCP Joint, Xiapex, PNF Active, not recruiting NCT02647619 Phase 4 Xiapex
44 Stereotactic Body Radiotherapy for Head and Neck Tumors Active, not recruiting NCT01344356 Phase 4
45 Fasciectomy vs Collagenase Injection in Recurrent Dupuytren Disease Enrolling by invitation NCT03406338 Phase 4 Collagenase Clostridium Histolyticum
46 Low Molecular Weight Heparin (LMWH) vs Aspirin for Venous Thromboembolism (VTE) Prophylaxis in Orthopaedic Oncology Enrolling by invitation NCT03244020 Phase 4 Aspirin 325mg;Enoxaparin 40Mg/0.4mL Prefilled Syringe
47 IVF Outcome Following Treatment With Ulipristal Acetate for Myomatous Uterus After at Least One IVF Failure Not yet recruiting NCT02601196 Phase 4 Ulipristal acetate
48 Preemptive Analgesia Following Uterine Artery Embolization Terminated NCT01555073 Phase 4 pregabalin/celecoxib;pregabalin/placebo;celecoxib/placebo;Placebo group
49 Study to Evaluate the Safety and Effectiveness of MRgFUS Compared With Myomectomy for the Treatment of Uterine Fibroids Terminated NCT01328067 Phase 4
50 Safety and Efficacy of Delayed Manipulation After Xiaflex Treatment in Subjects With Dupuytren's Contracture Terminated NCT01226121 Phase 4

Search NIH Clinical Center for Connective Tissue Cancer

Cochrane evidence based reviews: neoplasms, connective tissue

Genetic Tests for Connective Tissue Cancer

Anatomical Context for Connective Tissue Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Connective Tissue Cancer:

18
Connective Tissue

Publications for Connective Tissue Cancer

Articles related to Connective Tissue Cancer:

# Title Authors Year
1
Adherence to treatment guidelines for primary sarcomas affects patient survival: a side study of the European CONnective TIssue CAncer NETwork (CONTICANET). ( 23446092 )
2013
2
Long-term effects of connective tissue cancer treatment. ( 15346055 )
2004

Variations for Connective Tissue Cancer

Expression for Connective Tissue Cancer

Search GEO for disease gene expression data for Connective Tissue Cancer.

Pathways for Connective Tissue Cancer

GO Terms for Connective Tissue Cancer

Biological processes related to Connective Tissue Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.8 CD34 MDM2 PDGFB TLE1 TP53
2 response to drug GO:0042493 9.65 CDK4 COL1A1 MDM2 SS18 TP53
3 cellular response to growth factor stimulus GO:0071363 9.54 MDM2 PDGFB TRPV1
4 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.46 MDM2 PDGFB
5 cellular response to alkaloid GO:0071312 9.43 MDM2 TRPV1
6 positive regulation of cell cycle GO:0045787 9.33 CDK4 MDM2 TP53
7 paracrine signaling GO:0038001 9.32 CD34 PDGFB
8 cellular response to actinomycin D GO:0072717 8.96 MDM2 TP53
9 response to hyperoxia GO:0055093 8.8 CDK4 COL1A1 TP53

Molecular functions related to Connective Tissue Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.23 COL1A1 EWSR1 FUS MDM2 PDGFB TLE1
2 platelet-derived growth factor binding GO:0048407 8.96 COL1A1 PDGFB

Sources for Connective Tissue Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....